Hopital Prive Sainte Marie Chalon
- Address
- lock Available on a paid plan
Digestive System Diseases
At Hopital Prive Sainte Marie Chalon the oncology team studies pancreatic cancer in patients with unresectable locally advanced or metastatic disease, evaluating the potential of intensive first‑line regimens such as FOLFIRINOX to improve survival and quality of life.
- Efficacy of combination chemotherapy in advanced disease
- Safety and tolerability of intensive treatment protocols
- Impact on disease‑related event‑free survival
The trial aims to identify more effective therapeutic options for patients with aggressive pancreatic tumors, supporting better outcomes at this French research site.
Neoplasms
In the same department, researchers focus on anal squamous cell carcinoma, comparing an induction regimen of modified DCF (mDCF) followed by chemoradiotherapy with standard chemoradiotherapy alone to determine which approach offers superior disease control.
- Induction chemotherapy strategies for locally advanced tumors
- Optimization of chemoradiotherapy sequencing
- Evaluation of two‑year event‑free survival rates
This study seeks to refine treatment pathways for anal cancer patients, potentially establishing a new standard of care at the hospital.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Prive Sainte Marie Chalon
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparison of mFOLFIRINOX Versus Platinum-Etoposide in First-Line Chemotherapy for Metastatic Grade 3 Gastroenteropancreatic Neuroendocrine Carcinoma | Centre Hospitalier Universitaire De Dijon | Phase II | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 6 | Unknown | 2014-12-23 | 2025-08-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.